Opko Q2 FY26 net loss narrows to $8.4 million; revenue rises to $163.5 million
PUBT · 1d ago
Share
Listen to the news
- Opko Health Q2 2026 revenue rose 4.28% to $163.5 million; net loss narrowed to $8.4 million, or $0.01 per share.
- Operating loss improved to $7 million from $60 million a year earlier.
- Pharmaceuticals product revenue climbed to $42.9 million from $40.7 million, with Rayaldee revenue rising to $8.1 million from $7.2 million.
- IP and other revenue more than doubled to $46.1 million, driven by $29.4 million recognized from shares received under a Nicoya agreement amendment.
- Forecasts Q3 2026 total revenue of $131 million-$142 million; sees full-year total revenue of $560 million-$585 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271605PRIMZONEFULLFEED9798760) on July 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved